Brief Communication: Morphoproteomic analysis of osteolytic Langerhans cell histiocytosis with therapeutic implications

Annals of Clinical and Laboratory Science

Volumn 35, Issue 2, 2005, Pages 131-136

  Brown, Robert E ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

Langerhans cell histiocytosis; Morphoproteomics

Indexed keywords

AMINOBISPHOSPHONATES; BORTEZOMIB; DEXAMETHASONE; GAMMA INTERFERON; IMATINIB; INDOMETACIN; PHOSPHONIC ACID DERIVATIVE; RAPAMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; HISTIOCYTE; HISTIOCYTOSIS; HISTOGENESIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; STRUCTURAL PROTEOMICS; TUMOR CELL;

HISTIOCYTES; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOHISTOCHEMISTRY; OSTEOCLASTS; OSTEOLYSIS; PROTEOME;

EID: 18744388864     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Munn SE, Olliver L, Broadbent V, Pritchard J. Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol 1999;32:247-249.
2. Brown RE. Letter to the Editor: cyclo-oxygenase-2 in osteolytic lesions of Langerhans cell histiocytosis. Med Pediatr Oncol 2000;34:311.
3. Farran RP, Zaretski E, Egeler RM. Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol 2001;23:54-56.
4. Brown RE. Letter to the Editor: more on pamidronate in Langerhans-cell histiocytosis. NEJM 2001;345:1503.
5. Brown RE. Interferon-alpha therapy, protein kinase C-alpha and Langerhans' cell histiocytosis. Med Pediatr Oncol 2003;41:63-64.
6. Kanakaraj P, Raj S, Khan SA, Bishayee S. Ligand-induced interaction between alpha-and beta-type platelet-derived growth factor (PDGF) receptors: role of receptor heterodimers in kinase activation. Biochemistry 1991;30:1761-1767.
7. Chen QP, Giannobile WV. Adenoviral gene transfer of PDGF downregulates ras gene product PDGFalphaR and prolongs ERK and Akt/PKB activation. Am J Physiol - Cell Physiol 2002;282:C538-544.
8. Baron W, Decker L, Colognato H, ffrench-Constant C. Regulation of integrin growth factor interactions in oligodendrocytes by lipid raft microdomains. Curr Biol 2003;13:151-155.
9. Tsutsumi N, Yonemitsu Y, Shikada Y, Onimaru M, Tanii M, Okana S, Kaneko K, Hasegawa M, Hashizume M, Maehara Y, Sueishi K. Essential role of PDGFR-alpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFR alpha during angiogenesis. Circ Res 2004;94:1186-1194.
10. DeMali KA, Whiteford CC, Ulug ET, Kazlauskas A. Platelet-derived growth factor-dependent cellular transformation requires either phospholipase Cgamma or phosphatidylinositol 3 kinase. J Biol Chem 1997;272:9011-9018.
11. Rosenkranz S, DeMali KA, Gelderloos JA, Bazenet C, Kazlauskas A. Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. J Biol Chem 1999;274:28335-28343.
12. Assefa Z, Valius M, Vantus T, Agostinis P, Merlevede W, Vandenheede JR. JNK/SAPK activation by platelet-derived growth factor in A431 cells requires both the phospholipase C-gamma and the phosphatidylinositol 3-kinase signaling pathways of the receptor. Biochem Biophys Res Commun 1999;261:641-645.
13. Bai XC, Deng F, Liu AL, Zou ZP, Wang Y, Ke ZY, Ji QS, Luo SQ. Phospholipase C-gamma 1 is required for cell survival in oxidative stress by protein kinase C. Biochem J 2002;363:395-401.
14. Maier JA, Ragnotti G. An oligomer targeted against protein kinase C alpha prevents interleukin 1 alpha induction of cyclooxygenase expression in human endothelial cells. Exp Cell Res 1993;205:52-58.
15. Kreuzer J, Schmidts A, Marquetant R, Niebauer J, Strasser RH. Protein kinase C activation after cellular adhesion on fibronectin: partial suppression after inhibition of protein isoprenylation. Eur J Med Res 1997;2:305-310.
16. Bazenet CE, Kazlauskas A. The PDGF receptor alpha subunit activates p21ras and triggers DNA synthesis without interacting with rasGAP. Oncogene 1994;9:517-525.
17. Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi C, Jiang BH. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K / AKT / mTOR / p70S6K1 signaling in human ovarian cancer cells. Am J. Physiol-Cell Physiol 2004;287:C281-291.
18. Iwasaki H, Eguchi S, Ueno H, Marumo F, Hirata Y. Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology 1999;140:4659-4668.
19. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003;29:33-39.
20. Chen CC, Chen JJ, Chou CY. Protein kinase c alpha but not p44/42 mitogen-activated protein kinase, p38, or c-Jun NH(2)-terminal kinase is required for intercellular adhesion molecule-1 expression mediated by interleukin-1 beta: involvement of sequential activation of tyrosine kinase, nuclear factor-kappaB-inducing kinase, and IkappaB kinase 2. Mol Pharmacol 2000;58:1479-1489.
21. Vertegaal AC, Kuiperij HB, Yamaoka S, Courtois G, van der Eb AJ, Zantema A. Protein kinase C-alpha is an upstream activator of the IkappaB kinase complex in theTPA signal transduction pathway to NF-kappaB in U20S cells. Cell Signal 2000;12:759-768.
22. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999;401:86-90.
23. Matsue H, Yang C, Matsue K, Edelbaum D, Mummert M, Takashima A. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A and dexamethasone) on bidirectional dendritic cell-T-cell interaction during antigen presentation. J Immunol 2002;169:3555-3564.
24. Romano MF, Avellino R, Petrella A, Bisogni R, Romano S, Venuta S. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004;40:2829-2836.
25. Zhou L, Tan A, Iasvovskaia S, Li J, Lin A, Hershenson MB. Ras and mitogen-activated protein kinase kinase kinase-1 coregulate activator protein-1 and nuclear factor-κB-mediated gene expression in airway epithelial cells. Am J Respir Cell Mol Biol 2003;28:762-769.
26. Je JH, Lee JY, Jung KJ, Sung B, Go EK, Yu BP, Chung HY. NF-kappaB activation mechanism of 4-hydroxy-hexenal via NIK/IKK and p38 MAPK pathway. FEBS Lett 2004;566:183-189.
27. Regula KM, Ens K, Kirshenbaum LA. IKK beta is required for Bcl-2-mediated NF- kappaB activation in ventricular myocytes. J Biol Chem 2002;277:38676- 38682.
28. Shao J, Evers BM, Sheng H. Roles of phosphatidylinositol 3′-kinase and mammalian target to rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2004;64:229-235.
29. Savell VH Jr, Sherman T, Scheuermann RH, Siddiqui AM, Margraf LR. Bcl-2expression in Langerhans' cell histiocytosis. Ped Develop Pathol 1998;1:210-215.
30. Schouten B, Egeler RM, Leenen PJ, Taminiau AH, van den Broek LJ, Hogendoorn PC. Expression of cell cycle-related gene products in Langerhans cell histiocytosis. J Pediat Hematol/Oncol 2002;24:727-732.
31. Bae JS, Jang MK, Hong S, An WG, Choi YH, Kim HD, Cheong J. Phosphorylation of NF-kappaB by calmodulin-dependent kinase IV activates anti-apoptotic gene expression. Biochem Biophys Res Commun 2003;305:1094-1098.
32. Fosslien E. Molecular pathology of cyclooxygenase 2 in neoplasia. Ann Clin Lab Sci 2000;30:3-21.
33. Tee AR, Proud CG. Staurosporine inhibits phosphorylation of translational regulators linked to mTOR. Cell Death Diff 2001;8:841-849.
34. Morley SJ. Signalling through either the p38 or ERK mitogen-activated protein (MAP) kinase pathway is obligatory for phorbol ester and T cell receptor complex (TCR-CD3)-stimulated phosphorylation of initiation factor (eIF) 4E in Jurkat T cells. FEBS Lett 1997;418:327-332.
35. Herbert TP, Tee AR, Proud CG. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem 2002;277:11591-11596.
36. Polunovsky VA, Gingras AC, Sonenberg N, Peterson M, Tan A, Rubins JB, Manivel JC, Bitterman PB. Translational control of the antiapoptic function of Ras. J Biol Chem 2000;275:24776-24780.
37. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG. Inhibition of phosphatidyl inositol 3-kinase and ERK MAPK-regulated protein synthesis reveals the pro-apoptic properties of CD40 ligation in carcinoma cells. J Biol Chem 2004;279:1010-1019.
38. Ueda N, Koide M, Ohguchi M, Ishihara Y, Noguchi T, Okahashi N, Nishihara T. Involvement of prostaglandin E2 and interleukin-1 alpha in the differentiation and survival of osteoclasts induced by lipolysaccharide from Actinobacillus actinomycetemcomitans Y4. J Periodontal Res 1998;33:509-516.
39. Brown RE. Angiotensin-converting enzyme, transforming growth factor β1, and interleukin 11 in the osteolytic lesions of Langerhans cell histiocytosis. Arch Pathol Lab Med 2000; 124: 1287-1290.
40. Morinaga Y, Fujita N, Ohishi K, Zhang Y, Tsuruo T. Suppression of interleukin-11 mediated bone resorption by cyclooxygenase inhibitors. J Cell Physiol 1998;175:247-254.
41. Galvin RJ, Bryan P, Horn JW, Rippy MK, Thomas JE, Development and characterization of a porcine model to study osteoclast differentiation and activity. Bone 1996;19:271-279.
42. Arenzana-Seisdedos F, Barbey S, Virelizier JL, Kornprobst M, Nezelof C. Histiocytosis X purified (T6+) cells from bone granuloma produce interleukin-1 and prostaglandin E2 in culture. J Clin Invest 1986;77:326-329.
43. Buchdunger E, Cioffi CL, Law N, Strover D, Ohno-Jones S, Druker BJ, Lydon NB. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
44. Brown RE, Lun M, Prichard JW, Blasick TA, Zhang PL. Morphoproteomic and pharmacoproteomic correlates in hormone-receptor-negative breast carcinoma cell lines. Ann Clin Lab Sci 2004;34:251-262.
45. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-c containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
46. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-241.
47. Sabers CJ, Martin MM, Brunn GJ. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995;270:815-822.
48. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth dependent activation of and signaling by the 70kdS6 protein kinases. Cell 1992;69:1227-1236.
49. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein, DP, Anderson KC, A phase 2 study of bortezornib in relapsed, refractory myeloma. NEJM 2003;348:2609-2617.
50. Brown RE, Bostrom B, Zhang PL. Brief Communication: Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann Clin Lab Sci 2004;34:203-205.
51. Arzoo K, Sadeghi S, Pullarkat V. Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis. NEJM 2001;345:225.
52. Montella L, Insabato L, Pulmieri G. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. NEJM 2004;351:1034-1035.
53. Woltman AM, de Fijter JW, Kamerling SWA, van der Kooij SW, Paul LC, Daha MR, van Kooten C. Rapamycin inducers apoptosis in monocyte-and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001;98:174-180.